A vaccine to protect against chlamydia is now a step closer to becoming reality after a pioneering clinical trial has found the treatment to be safe.
Researchers from the Imperial College London and the Statens Serum Institut in Copenhagen tested two formulations of a vaccine, with each type given to 15 women aged between 19 and 45. Another five women were given a placebo.
All participants received three injections into their arm over four months, followed by two doses administered through a nasal spray in the weeks after.
Neither the women nor those monitoring the impact of the vaccine were aware of who was in which group.
Both formulations appeared to be safe, however researchers state that one stood out as a front runner and are now set to move this vaccine into the next phase of testing.
While further trials need to be carried out to determine whether it can fully protect against the infection, experts say it is an “important first step” in tackling the condition.